Home › Myasthenia Gravis › Illinois › Chicago
Myasthenia Gravis clinical trials in Chicago, IL
4 studies for Myasthenia Gravis are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecruitingPhase 1/2
- Northwestern Memorial Hospital, Chicago
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
RecruitingPhase 1/2
- Aurinia Investigational Site, Chicago
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
RecruitingPhase 4
- Research Site, Chicago
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RecruitingPhase 2/3
- Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago
About Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
More about Myasthenia Gravis on MedlinePlus
Myasthenia Gravis trials in other cities
- Tampa, FL12 studies
- Houston, TX11 studies
- Durham, NC10 studies
- Boca Raton, FL10 studies
- Columbus, OH8 studies
- Milwaukee, WI7 studies
- St. Louis, MO7 studies
- New York City, NY7 studies
- Miami, FL7 studies
- Washington, DC6 studies
- Columbia, MO6 studies
- Chattanooga, TN6 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity41 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Colorectal Cancer33 studies
- Heart Failure31 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.